Author:
Reoma Lauren B.,Karp Barbara Illowsky
Funder
National Institute of Neurological Disorders and Stroke
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Neurology (clinical),Pharmacology
Reference26 articles.
1. Hutchinson N, Carlisle B, Doussau A, et al. Patient participation in clinical trials of oncology drugs and biologics preceding approval by the US Food and Drug Administration. JAMA Netw Open. 2021;4: e2110456.
2. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323:844–53.
3. Brown DG, Wobst HJ, Kapoor A, Kenna LA, Southall N. Clinical development times for innovative drugs. Nat Rev Drug Discov 2021.
4. Burns TM, Crowell JL, Smith AG. A crisis in US drug pricing: consequences for patients with neuromuscular diseases, physicians and society, part 1. Muscle Nerve. 2020;62:567–72.
5. Congress T. Public Law. 1983;97–414. Orphan Drug Act [online]. Available at: https://www.govinfo.gov/content/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献